604 related articles for article (PubMed ID: 32144034)
1. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
2. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
Doggrell SA
Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
[TBL] [Abstract][Full Text] [Related]
5. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Kuthe A
Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
[TBL] [Abstract][Full Text] [Related]
7. Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction.
von Büren M; Rodler S; Wiesenhütter I; Schröder F; Buchner A; Stief C; Gratzke C; Wülfing C; von Büren J
Eur Urol Focus; 2022 May; 8(3):794-802. PubMed ID: 34006491
[TBL] [Abstract][Full Text] [Related]
8. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
[TBL] [Abstract][Full Text] [Related]
9. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
11. Management of ED under the "severe distress" criteria in the NHS: a real-life study.
Mohee A; Bretsztajn L; Storey A; Eardley I
J Sex Med; 2014 Apr; 11(4):1056-1062. PubMed ID: 24382018
[TBL] [Abstract][Full Text] [Related]
12. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
[TBL] [Abstract][Full Text] [Related]
14. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
15. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
Ströberg P; Murphy A; Costigan T
Clin Ther; 2003 Nov; 25(11):2724-37. PubMed ID: 14693300
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
[TBL] [Abstract][Full Text] [Related]
17. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
18. Clinical monograph for drug formulary review: erectile dysfunction agents.
Campbell HE
J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
[TBL] [Abstract][Full Text] [Related]
19. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
20. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
